Skip to main content
ICUI
NASDAQ Industrial Applications And Services

ICU Medical Q3 EPS $1.07, Gross Margin 41.9%, $120.6M Term Loan B Paydown

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$169
Mkt Cap
$4.192B
52W Low
$113.37
52W High
$192.85
52W Position info
49% above low
Off High info
12% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

ICUI sits 49% above its 52-week low of $113.37 on elevated volume (2.1× avg).

Summary

ICU Medical's Q3 10-Q confirms $1.07 EPS on $560.4 million revenue with gross margin up to 41.9%, and shows $218.6 million of nine-month operating cash flow funding $134.7 million of debt paydown; the unresolved 2025 FDA Warning Letter on two pump lines remains the key risk.


Key Events · Earnings and Guidance · ICUI

  • Q3 EPS $1.07 on $560.4M Revenue

    Revenue rose 4.4% to $560.4 million from $537.0 million, with Infusion Systems up 10.7% on roughly $16 million of higher LVP hardware volume.

  • Gross Margin 41.9%, Tariff Refund Aided

    Margin expanded from 37.4%, including a $10.4 million (1.9 point) tariff refund; management does not expect further material IEEPA refunds.

  • Debt Paydown Leaves Term Loan B Clear to 2029

    Nine-month principal payments totaled $134.7 million, including $45.3 million and $75.3 million Term Loan B prepayments in Q2 and Q3 2026; no mandatory Term Loan B amortization until 2029.

  • 2026 Capex Outlook Cut to ~$75M

    Capital expenditure guidance was lowered from the previously disclosed $85 million to $100 million range due to project timing.


Analysis · ICUI · Industrial Applications And Services

The headline EPS of $1.07 was already out via Dow Jones and a same-day 8-K, so the print itself is not new. What the full 10-Q adds is the quality of the quarter and the balance-sheet trajectory: revenue of $560.4 million rose 4.4% on Infusion Systems growth, gross margin jumped to 41.9% from 37.4% partly on a $10.4 million tariff refund that will not repeat, and nine-month operating cash flow of $218.6 million more than funded $134.7 million of debt repayment. Management also cut the 2026 capex plan to about $75 million from the prior $85-100 million range. Against that, the 2025 FDA Warning Letter remains unresolved — the company withdrew its 510(k) applications for the MedFusion and CADD pumps and must resubmit after more testing, which keeps a regulatory overhang on the Infusion Systems franchise.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ICUI was trading at $169.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $113.37 to $192.85. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ICUI - Latest Insights

ICUI
Nov 05, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $167.65
Real-time Price: $172.52 info
Change: +$4.87 (+3%) info
Market Cap: $4.315B info
ICUI
Aug 06, 2026, 4:36 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $174.28
Real-time Price: $172.52 info
Change: -$1.76 (-1%) info
Market Cap: $4.315B info
ICUI
Aug 06, 2026, 4:34 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $174.28
Real-time Price: $172.52 info
Change: -$1.76 (-1%) info
Market Cap: $4.315B info
ICUI
Aug 06, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $174.28
Real-time Price: $172.52 info
Change: -$1.76 (-1%) info
Market Cap: $4.315B info
ICUI
May 18, 2026, 12:35 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $120.89
Real-time Price: $172.52 info
Change: +$51.64 (+43%) info
Market Cap: $4.315B info